首页 > 最新文献

Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

英文 中文
Rapid Predictive Dosimetry Is Now Freely Available. 快速预测剂量法现在是免费的。
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.125.270536
Yung Hsiang Kao
{"title":"Rapid Predictive Dosimetry Is Now Freely Available.","authors":"Yung Hsiang Kao","doi":"10.2967/jnumed.125.270536","DOIUrl":"10.2967/jnumed.125.270536","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1499-1500"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct Prognostic Roles of 18F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma. 18F-FDG - PET代谢反应在局部食管鳞状细胞癌诱导化疗或放化疗后的预后作用
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.125.269775
Yeong Hak Bang, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Jin-Sook Ryu, Yong-Il Kim, Joon Seon Song, Sung-Bae Kim, Sook Ryun Park

The prognostic significance of metabolic response by posttreatment 18F-FDG PET in esophageal squamous cell carcinoma (ESCC) treated with chemoradiotherapy remains unclear, particularly regarding metabolic response after induction chemotherapy versus after chemoradiotherapy. This study aimed to evaluate and compare their prognostic impact. Methods: This retrospective study analyzed 604 patients with localized ESCC who received induction chemotherapy followed by chemoradiotherapy, with or without surgery, at Asan Medical Center between 2006 and 2018. Metabolic responses after induction chemotherapy (before chemoradiotherapy) and after chemoradiotherapy were evaluated using European Organisation for Research and Treatment of Cancer-based criteria adapted for prognostic assessment. Results: In patients treated with definitive chemoradiotherapy (bimodality therapy), metabolic response after both induction chemotherapy and chemoradiotherapy was significantly associated with progression-free survival (PFS) and overall survival (OS). Complete metabolic response after induction chemotherapy correlated with the longest survival (PFS, 58.9 mo; OS, 90.8 mo), whereas progressive metabolic disease predicted poor prognosis (PFS, 3.7 mo; OS, 7.0 mo; P < 0.001). A similar pattern was observed for postchemoradiotherapy metabolic response. In patients who underwent surgery (trimodality therapy), metabolic response after induction chemotherapy did not significantly impact survival. However, in patients for whom surgery was initially planned, it remained prognostic, suggesting its prognostic relevance in the preoperative setting. Postchemoradiotherapy metabolic response was a strong independent prognostic factor in both bimodality therapy and trimodal therapy. Patients with diffuse esophagitis after chemoradiotherapy had intermediate survival outcomes, among complete metabolic response and partial metabolic response groups, indicating a distinct prognostic pattern. Conclusion: Postchemoradiotherapy metabolic response is a strong prognostic marker in localized ESCC, supporting its use for risk stratification. Early metabolic response after induction chemotherapy may also inform treatment decisions, particularly in surgery-intended patients.

食管鳞状细胞癌(ESCC)放化疗后18F-FDG PET代谢反应的预后意义尚不清楚,特别是诱导化疗后与放化疗后的代谢反应。本研究旨在评估和比较它们对预后的影响。方法:本回顾性研究分析了2006年至2018年峨山医疗中心604例局部ESCC患者,这些患者接受了诱导化疗和放化疗,伴或不伴手术。诱导化疗后(放化疗前)和放化疗后的代谢反应采用欧洲癌症研究和治疗组织的预后评估标准进行评估。结果:在接受终期放化疗(双峰治疗)的患者中,诱导化疗和放化疗后的代谢反应与无进展生存期(PFS)和总生存期(OS)显著相关。诱导化疗后完全代谢缓解与最长生存期(PFS, 58.9个月;OS, 90.8个月),而进行性代谢性疾病预测预后不良(PFS, 3.7个月;OS, 7.0 mo;P < 0.001)。在放化疗后的代谢反应中也观察到类似的模式。在接受手术(三段式治疗)的患者中,诱导化疗后的代谢反应对生存率没有显著影响。然而,在最初计划手术的患者中,它仍然是预后,表明其与术前设置的预后相关。放化疗后代谢反应在双峰治疗和三峰治疗中都是一个强大的独立预后因素。在完全代谢缓解组和部分代谢缓解组中,放化疗后弥漫性食管炎患者的生存结果中等,表明预后模式不同。结论:放化疗后代谢反应是局限性ESCC的一个强有力的预后指标,支持将其用于风险分层。诱导化疗后的早期代谢反应也可以为治疗决策提供信息,特别是在手术患者中。
{"title":"Distinct Prognostic Roles of <sup>18</sup>F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma.","authors":"Yeong Hak Bang, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Jin-Sook Ryu, Yong-Il Kim, Joon Seon Song, Sung-Bae Kim, Sook Ryun Park","doi":"10.2967/jnumed.125.269775","DOIUrl":"10.2967/jnumed.125.269775","url":null,"abstract":"<p><p>The prognostic significance of metabolic response by posttreatment <sup>18</sup>F-FDG PET in esophageal squamous cell carcinoma (ESCC) treated with chemoradiotherapy remains unclear, particularly regarding metabolic response after induction chemotherapy versus after chemoradiotherapy. This study aimed to evaluate and compare their prognostic impact. <b>Methods:</b> This retrospective study analyzed 604 patients with localized ESCC who received induction chemotherapy followed by chemoradiotherapy, with or without surgery, at Asan Medical Center between 2006 and 2018. Metabolic responses after induction chemotherapy (before chemoradiotherapy) and after chemoradiotherapy were evaluated using European Organisation for Research and Treatment of Cancer-based criteria adapted for prognostic assessment. <b>Results:</b> In patients treated with definitive chemoradiotherapy (bimodality therapy), metabolic response after both induction chemotherapy and chemoradiotherapy was significantly associated with progression-free survival (PFS) and overall survival (OS). Complete metabolic response after induction chemotherapy correlated with the longest survival (PFS, 58.9 mo; OS, 90.8 mo), whereas progressive metabolic disease predicted poor prognosis (PFS, 3.7 mo; OS, 7.0 mo; <i>P</i> < 0.001). A similar pattern was observed for postchemoradiotherapy metabolic response. In patients who underwent surgery (trimodality therapy), metabolic response after induction chemotherapy did not significantly impact survival. However, in patients for whom surgery was initially planned, it remained prognostic, suggesting its prognostic relevance in the preoperative setting. Postchemoradiotherapy metabolic response was a strong independent prognostic factor in both bimodality therapy and trimodal therapy. Patients with diffuse esophagitis after chemoradiotherapy had intermediate survival outcomes, among complete metabolic response and partial metabolic response groups, indicating a distinct prognostic pattern. <b>Conclusion:</b> Postchemoradiotherapy metabolic response is a strong prognostic marker in localized ESCC, supporting its use for risk stratification. Early metabolic response after induction chemotherapy may also inform treatment decisions, particularly in surgery-intended patients.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1352-1364"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals. 上述非临床剂量学研究支持某些PET放射性药物的首次人体研究。
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.125.270320
Donika Plyku, Hayoung Koo, Luke Park, August Hofling, Libero Marzella
{"title":"Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals.","authors":"Donika Plyku, Hayoung Koo, Luke Park, August Hofling, Libero Marzella","doi":"10.2967/jnumed.125.270320","DOIUrl":"10.2967/jnumed.125.270320","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1497"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals". 回复“上述非临床剂量学研究以支持某些PET放射性药物的首次人体研究”。
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.125.270467
Marianna Dakanali, Steven S Zigler, Sally W Schwarz, Michael L Nickels, Reiko Oyama, Henry F VanBrocklin, Peter J H Scott
{"title":"Reply to \"Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals\".","authors":"Marianna Dakanali, Steven S Zigler, Sally W Schwarz, Michael L Nickels, Reiko Oyama, Henry F VanBrocklin, Peter J H Scott","doi":"10.2967/jnumed.125.270467","DOIUrl":"10.2967/jnumed.125.270467","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1497-1498"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining Nuclear Medicine: "Biodistribution" Should Be the Core Concept. 重新定义核医学:“生物分布”应该是核心概念。
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.125.270245
Celso Dario Ramos
{"title":"Redefining Nuclear Medicine: \"Biodistribution\" Should Be the Core Concept.","authors":"Celso Dario Ramos","doi":"10.2967/jnumed.125.270245","DOIUrl":"10.2967/jnumed.125.270245","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1498"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[68Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear Factor-κB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with Histopathology. [68Ga]Ga-FAPI PET/CT监测骨巨细胞瘤对核因子-κB配体抑制剂受体激活物的反应:与组织病理学的相关性。
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.124.269432
Wenjie Zhang, Wenqing Yao, Guohua Shen
{"title":"[<sup>68</sup>Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear Factor-κB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with Histopathology.","authors":"Wenjie Zhang, Wenqing Yao, Guohua Shen","doi":"10.2967/jnumed.124.269432","DOIUrl":"10.2967/jnumed.124.269432","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1493"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Influenza B Virus-Associated Cerebellitis Detected by 18F-FDG PET/CT Imaging. 18F-FDG PET/CT检测1例罕见乙型流感病毒相关小脑炎。
IF 9.1 Pub Date : 2025-09-02 DOI: 10.2967/jnumed.125.269548
Hukui Sun, Dayan Cheng, Xiangde Du, Chengwei Sun, Jiahui Zhang
{"title":"A Rare Influenza B Virus-Associated Cerebellitis Detected by <sup>18</sup>F-FDG PET/CT Imaging.","authors":"Hukui Sun, Dayan Cheng, Xiangde Du, Chengwei Sun, Jiahui Zhang","doi":"10.2967/jnumed.125.269548","DOIUrl":"10.2967/jnumed.125.269548","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1494"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel? 放射性药物治疗还是卡巴他赛?
IF 9.1 Pub Date : 2025-08-01 DOI: 10.2967/jnumed.125.269875
Michael Froehner, Klaus Zöphel
{"title":"<sup>177</sup>Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?","authors":"Michael Froehner, Klaus Zöphel","doi":"10.2967/jnumed.125.269875","DOIUrl":"10.2967/jnumed.125.269875","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1315"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2024 SNMMI Highlights Lecture: Neurosciences. 2024 SNMMI重点讲座:神经科学。
IF 9.1 Pub Date : 2025-08-01 DOI: 10.2967/jnumed.125.270521
Richard Carson

The Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 y by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of summarizing selected significant presentations at the meeting were divided annually among 4 distinguished nuclear and molecular medicine subject matter experts. The 2024 Highlights Lectures were delivered on June 11, 2024, at the SNMMI Annual Meeting in Toronto, Canada. Presented here is the lecture by Richard Carson, PhD, Professor of Radiobiology and Biomedical Imaging and of Biomedical Engineering at Yale School of Medicine (New Haven, CT), who spoke on neuroscience topics presented at the meeting. Note that in the following presentation summary, numerals in brackets represent abstract numbers as published in The Journal of Nuclear Medicine (2024;65[suppl 2]).

在每次SNMMI年会的闭幕会议上发表的亮点演讲,由Henry N. Wagner, Jr., MD发起并发表了30多年。从2010年开始,总结会议上精选的重要演讲的职责每年由4位杰出的核与分子医学主题专家进行划分。2024年重点讲座于2024年6月11日在加拿大多伦多举行的SNMMI年会上发表。下面是耶鲁大学医学院(纽黑文,CT)放射生物学和生物医学成像及生物医学工程教授Richard Carson博士的演讲,他在会议上就神经科学主题发表了演讲。请注意,在以下简报摘要中,括号内的数字表示发表在《核医学杂志》(2024;65[增刊2])上的摘要数字。
{"title":"2024 SNMMI Highlights Lecture: Neurosciences.","authors":"Richard Carson","doi":"10.2967/jnumed.125.270521","DOIUrl":"10.2967/jnumed.125.270521","url":null,"abstract":"<p><p><i>The Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 y by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of summarizing selected significant presentations at the meeting were divided annually among 4 distinguished nuclear and molecular medicine subject matter experts. The 2024 Highlights Lectures were delivered on June 11, 2024, at the SNMMI Annual Meeting in Toronto, Canada. Presented here is the lecture by Richard Carson, PhD, Professor of Radiobiology and Biomedical Imaging and of Biomedical Engineering at Yale School of Medicine (New Haven, CT), who spoke on neuroscience topics presented at the meeting. Note that in the following presentation summary, numerals in brackets represent abstract numbers as published in</i> The Journal of Nuclear Medicine <i>(2024;65[suppl 2]).</i></p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1176-1183"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Translating Discovery into Impact: Owen Witte Talks with Caius Radu and Johannes Czernin About a Life Dedicated to Science and Discovery. 改变职业重心:欧文·维特与凯斯·拉杜和约翰内斯·切尔宁谈致力于科学和发现的生活。
IF 9.1 Pub Date : 2025-08-01 DOI: 10.2967/jnumed.125.270520
Owen Witte, Caius Radu, Johannes Czernin
{"title":"Translating Discovery into Impact: Owen Witte Talks with Caius Radu and Johannes Czernin About a Life Dedicated to Science and Discovery.","authors":"Owen Witte, Caius Radu, Johannes Czernin","doi":"10.2967/jnumed.125.270520","DOIUrl":"10.2967/jnumed.125.270520","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1157-1159"},"PeriodicalIF":9.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1